CTRI/2019/04/018856尚未招募未知
An open-label, randomized, balanced, single dose, two-treatment, two-sequence, two-period, two-way crossover oral bioequivalence study of Clopidogrel Tablets, USP 300 mg Manufactured by Polygen Pharmaceuticals Inc. with PLAVIX® (clopidogrel bisulfate) tablets, 300 mg Distributed by Bristol-Myers Squibb/Sanofi Pharmaceuticals Partnership Bridgewater, NJ 08807 in healthy, adult, human subjects under fasting conditions
Polygen Pharmaceuticals Inc0 个研究点目标入组 0 人开始时间: 待定最近更新:
试验速览
- 阶段
- 未知
- 状态
- 尚未招募
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Ba/be
入排标准
入选标准
- •i. Subjects who are able to understand and provide written informed consent.
- •ii. Subjects must be healthy, adult, human beings within 18-45 years of age (both inclusive) weighing at least 50 kgs.
- •iii. Having a Body Mass Index (BMI) between 18.50 and 24.90 (both inclusive), calculated as weight in Kg/height in m2.
- •iv.Subjects must be of normal health as determined by medical history and physical examination performed within 28 days prior to the dosing (excluding screening day and check-in day) of 1st period.
- •v.Have normal ECG, chest X-ray and vital signs (Oral Temperature-950F to 990F, Pulse rate-60 to 100 per minute, Respiratory rate 14-20 per minute, Systolic blood pressure-90 to 140 mm/Hg and Diastolic blood pressure-60 to 90 mm/Hg).
- •vi.Subjects whose screening laboratory values are within normal limits or laboratory abnormalities considered by the investigator to be of no clinical significance.
- •vii.Availability of the subject for the entire study period and willingness to adhere to the protocol requirements as evidenced by written informed consent.
- •viii.If study participant is a female volunteer and is of child bearing potential practicing an acceptable method of birth control for the duration of the study as judged by the investigator(s), such as condoms, foams, jellies, diaphragm, intrauterine device (IUD)
- •Or abstinence
- •Or is postmenopausal for at least 1 year or is surgically sterile (bilateral tubal ligation, bilateral Oophorectomy or hysterectomy has been performed on the study participant).
- •ix.Female study participant will be given a negative serum pregnancy test at screening, check-in for all periods and at the time of post-study.
排除标准
- •i.History of hypersensitivity or idiosyncratic reaction to Clopidogrel or any other related drugs.
- •ii.Subjects with history or presence of significant cardiovascular, respiratory, hepatic, renal, hematological, gastrointestinal, endocrine, immunologic, dermatologic, neurological or psychiatric diseases.
- •iii.Subjects positive for HIV antibody, HCV and Hepatitis B surface antigen.
- •iv.Subject with any history of active bleeding such as stomach ulcer or bleeding in the brain.
- •v.History of medication or current use of Aspirin.
- •vi.Consumption of grapefruit and its juice for the past 03 days prior to the check-in day until the completion of the study.
- •vii.Subjects who have taken over the counter or prescribed medications within 7 days and enzyme modifying medication or any systemic medication (either prescribed or over-the-counter Including Herbal Preparation) during the last 7 days of study initiation and till completion of study and Monoamine Oxidase inhibitor (MAOI) within 14 days of study initiation and till completion of study.
- •viii.Study participants who have a history of alcohol or substance abuse within the last 1 year.
- •ix.Subjects who are in habit of consuming Ghutka, panmasala, tobacco products.
- •x.History of chronic smoking (more than 10 units per day of cigarettes, bidis, or any other form) or chronic consumption of tobacco products.
- •xi.Subject had diarrhea in the last 24 hrs which leads to dehydration.
- •xii.Subjects have abnormal value of bleeding time.
- •xiii.Study participants who have participated in any other clinical investigation using experimental drug or had blood loss of more than 350 mL at single occasion in the past 90 days.
- •xiv.Study participants with positive breath alcohol, positive urine screen for drugs of abuse.
- •xv.Female subjects who are pregnant or planning (women with child bearing potential) to become pregnant during the study.
- •xvi.Female volunteers who are currently breast feeding.
研究者
相似试验
已完成
1 期
A clinical trial study to determine the oral bio-availability of Caffxtend capsules.CTRI/2021/06/034185Inventia Healthcare Limited16
已完成
1 期
A clinical trial study to determine the bioavailability of different formulations of curcumin tablets.CTRI/2021/06/034356KMS Health Center Pvt Ltd
尚未招募
Unknown
Bioequivalence study of Propiomazine Tablets 25 mg in healthy, adult, human Subjects under fasting conditions.CTRI/2024/04/066196Centaur Pharmaceuticals Pvt. Ltd
已完成
不适用
3 PERIOD FASTING STUDY IN HEALTHY, ADULT, MALES, RANDOMLY DOSED IN EACH PERIOD WITH 2000mg OF CURCUMINOIDS FROM LIQUID CURCUMIN or with CURCUMINOID POWDER WITH TURMERIC ESSENTIAL OIL IN VEGETARIAN CAPSULES OR WITH CURCUMINOID POWDER WITH PIPERINE IN VEGETARIAN CAPSULESCTRI/2019/04/018513Halycon Bioscience pty Ltd9
尚未招募
1 期
A randomized, open label, balanced, single-dose, two-formulation, two-sequence, two-period, two-way crossover oral bioequivalence study of test product of Empagliflozin 25 mg Tablets and Jardiance (Empagliflozin 25 mg Tablets) in healthy, adult Thai volunteers under fasting conditionsHealthy volunteersBioequivalenceEmpagliflozinPharmacokineticsTCTR20220209004ovartis (Thailand) Ltd.32